Who is sponsoring NCT00199420?

NCT00199420 is sponsored by Kyowa Kirin, Inc..

What condition does NCT00199420 study?

NCT00199420 studies Parkinson's Disease.

What drugs are being tested in NCT00199420?

Interventions: Istradefylline (KW-6002).

What is the status of NCT00199420?

NCT00199420 is currently COMPLETED.

Last reviewed 2024-04-23 · How we verify

A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.

NCT00199420 Phase 3 COMPLETED

To establish the efficacy of 10, 20 and 40 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.

Details

Lead sponsor	Kyowa Kirin, Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	580
Start date	2004-07
Completion	2005-12

Conditions

Parkinson's Disease

Interventions

Istradefylline (KW-6002)

Primary outcomes

To establish the efficacy of 10, 20 and 40 mg/d istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa/carbidopa.

Countries

United States